Vaxcyte Capital Surpluse from 2010 to 2024

PCVX Stock  USD 89.40  1.01  1.14%   
Vaxcyte Capital Surpluse yearly trend continues to be fairly stable with very little volatility. Capital Surpluse is likely to outpace its year average in 2024. During the period from 2010 to 2024, Vaxcyte Capital Surpluse regression line of annual values had r-squared of  0.70 and arithmetic mean of  206,134,515. View All Fundamentals
 
Capital Surpluse  
First Reported
2010-12-31
Previous Quarter
670.3 M
Current Value
703.8 M
Quarterly Volatility
302.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vaxcyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxcyte's main balance sheet or income statement drivers, such as Interest Income of 66.1 M, Interest Expense of 0.0 or Selling General Administrative of 63.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.16. Vaxcyte financial statements analysis is a perfect complement when working with Vaxcyte Valuation or Volatility modules.
  
Check out the analysis of Vaxcyte Correlation against competitors.
For more information on how to buy Vaxcyte Stock please use our How to Invest in Vaxcyte guide.

Latest Vaxcyte's Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of Vaxcyte over the last few years. It is Vaxcyte's Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaxcyte's overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

Vaxcyte Capital Surpluse Regression Statistics

Arithmetic Mean206,134,515
Geometric Mean6,100,874
Coefficient Of Variation146.86
Mean Deviation273,789,754
Median452,000
Standard Deviation302,719,800
Sample Variance91639.3T
Range703.3M
R-Value0.83
Mean Square Error29920.3T
R-Squared0.70
Significance0.0001
Slope56,504,945
Total Sum of Squares1282949.9T

Vaxcyte Capital Surpluse History

2024703.8 M
2023670.3 M
2021582.8 M
2020544.4 M
2019M
20181.3 M

About Vaxcyte Financial Statements

Vaxcyte investors use historical fundamental indicators, such as Vaxcyte's Capital Surpluse, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vaxcyte. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Surpluse670.3 M703.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vaxcyte Stock Analysis

When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.